tlooto
Sign up
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentProstate Cancer Treatment and Research

The optimal choice for maintenance therapy in ovarian cancer with HR-proficient (HRp)/unknown status: A comparison of Bevacizumab and Niraparib

Qiaqia Li, Ting Wan, Linyu Wu, Jundong Li

2026.5.1Gynecologic Oncology

DOI: 10.1016/j.ygyno.2026.01.347

Abstract

Abstract is not available.

Citation format

LI, Qiaqia, et al. The optimal choice for maintenance therapy in ovarian cancer with HR-proficient (hrp)/unknown status: A comparison of bevacizumab and niraparib. Gynecologic Oncology, 2026, 208: S182-S183.